Remote Heart Surgery Robot Startup Raises $62M

Remedy Robotics' AI-assisted system is still in development, with the new funds aimed at clinical trials and eventual FDA review.

Updated on Nov. 17, 2026 in Robotics

Photograph of a white robotic surgical arm above an empty operating table in a bare clinical theater with cool overhead light.
Remedy Robotics raised $62 million in a Series B round led by DCVC to fund clinical trials of its AI-assisted remote heart surgery robot ahead of FDA review. AI Illustration. Upload story photo >

Live Poll

Would you trust a robot-assisted heart procedure guided remotely by a doctor?

Remedy Robotics, a San Francisco-based medical robotics company founded in Australia, raised $62 million in a Series B funding round led by DCVC, a US venture capital firm. The company's AI-powered robotic system is designed to let doctors perform complex cardiovascular procedures remotely; the system is described as in development, not as a shipped product.

Why it matters

The round funds clinical trials and work toward US Food and Drug Administration approval, so remote cardiovascular robotics is moving from concept toward regulated human testing. New participation from university and pension-linked investors signals that institutional capital is willing to back this stage of medical robotics.

The source reports a $62 million Series B round and describes an AI-powered robotic system for remote cardiovascular procedures, but gives no performance benchmarks, procedure success rates, or device specifications. The figures available are financial, not technical, so the system's capabilities remain unverified outside the company's own description.

The players

DCVC

DCVC is a US venture capital firm that led Remedy Robotics' $62 million Series B round.

UC Investments

UC Investments is the University of California's investment fund, which invested in the round and is partnering with Remedy Robotics on clinical trials.

Remedy Robotics

Remedy Robotics is a San Francisco medical robotics company founded in Australia that is developing AI-assisted robotic systems for remote cardiovascular procedures.

The details

Remedy Robotics builds a robotic system that uses artificial intelligence to assist physicians during complex cardiovascular procedures, with the surgeon operating the system from a location separate from the patient. The round will fund clinical trials, the controlled studies in human patients that regulators require before a medical device can be sold. Skip Capital, Hostplus, HESTA, and UC Investments are new investors, while Blackbird, Build Collective, Divergent Capital, and KdT Ventures returned.

Timeline

  1. November 16, 2026: Series B funding round announced

The Tech Race

Remedy Robotics is pursuing remote cardiovascular robotics at a stage where clinical trials, not yet commercial sales, are the next milestone. The source does not name specific competing programs, so the company's position relative to rivals cannot be assessed from the extraction.

Patients needing complex cardiovascular procedures are not affected by this round yet, since the system remains in development and has no announced availability date. Any benefit would depend on clinical trial results and FDA approval, neither of which the source gives a timeline for.

The takeaway

The funding signals that remote cardiovascular robotics is entering the regulated trial phase in the United States. Watch for the first announced clinical trial enrollment from Remedy Robotics and UC Investments, which would show the program has moved from funding to patients.

Further reading

For more on how surgical systems are moving toward regulated human use, see Robotics coverage across the United States.

Live Poll

Would you trust a robot-assisted heart procedure guided remotely by a doctor?